

=> b reg  
 FILE 'REGISTRY' ENTERED AT 13:03:49 ON 08 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JAN 2010 HIGHEST RN 1201136-14-2  
 DICTIONARY FILE UPDATES: 6 JAN 2010 HIGHEST RN 1201136-14-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 19  
 L7 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE  
 L9 665 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 2627 ITERATIONS 665 ANSWERS  
 SEARCH TIME: 00.00.01

=> b zcap  
 FILE 'ZCAPLUS' ENTERED AT 13:04:04 ON 08 JAN 2010  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
 held by the publishers listed in the PUBLISHER (PB) field (available  
 for records published or updated in Chemical Abstracts after December  
 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the  
 American Chemical Society and is provided to assist you in searching  
 databases on STN. Any dissemination, distribution, copying, or storing  
 of this information, without the prior written consent of CAS is  
 strictly prohibited.

FILE COVERS 1907 - 8 Jan 2010 VOL 152 ISS 3

FILE LAST UPDATED: 7 Jan 2010 (20100107/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

ZCAplus now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d bib abs hitrn fhitr 112 tot

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)  
AN 2005:638879 ZCAPLUS  
DN 143:153410

II Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases  
IN Kshirsagar, Tushar A.; Griesgraber, George W.; Celebi, Abdulaziz A.; Heppner, Philip D.  
PA 3M Innovative Properties Company, USA  
DO PCT Int. Appl., 218 pp.  
ST CODEN: PIXX22  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-----2005066172	A1	20050721	2004WO-US0043474	20041222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CP, CU, EE, DE, DK, DM, ES, EC, EG, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SH, SI, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VE, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SE, SZ, UG, ZM, ZW, AM, AE, AY, KG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU-----2004312510	A1	20050721	2004AU-000312510	20041222
CA-----2552101	A1	20050721	2004CA-002552101	20041222
EP-----1699792	A1	20060913	2004EP-000815538	20041222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, TE, SI, LT, FI, RO, MK, CY, AS, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN-----1922178	A	20070228	2004CN-080042200	20041222
JP-----200730450	T	20071101	2006JP-000547424	20041222
IN-----200602371	A	20070706	2006IN-000002371	20060628
US-----20070167476	A1	20070719	2007US-000596895	20070116
PRAI 200JUS-00533024P	P	20071129		
2004WO-US0043474	W	20041222		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSLUS DISPLAY FORMAT  
CS CASREACT 143:153410; MARPAT 143:153410  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [PA, RB = independently H, halo, alkenyl, alkoxy, alkylthio, NH2 and derivs.; or RACCRB = (unsubstituted fused hetero/aryl, fused 5- to 7-membered saturated ring; Z = a bond, alkylene; Z = (unsubstituted alkylene; with the proviso that the total number of C atoms contributed by Z and Z = 1-3; Y = a bond, SO2, SO2-NH and derivs., CO, etc.; R = halo, OH, alkenyl, haloalkyl, alkoxy, alkylthio, NH2 and derivs.; RI = H, (unsubstituted alken/ynyl), hetero/aryl, etc. with proviso]; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared via cyclocondensation of 1,2-diamine derivative III with chloroacetyl chloride, cyclization of imidazoquinoline, ROC-deprotection, chlorosulfonation of amine (not isolated) with MeSO2Cl, oxidation/amination with NH4OH, and TDMGS-deprotection. Certain I modulated cytokine biosynthesis by inhibiting production of interferon  $\alpha$  and/or tumor necrosis factor TNF- $\alpha$  when tested in an in vitro blood cell system.  
IT 1044675-88-8 1044675-97-9 1044676-02-9  
RI: PRPH (Prophetic)  
(Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)

860164-31-4P	860164-33-6P	860164-35-8P
860164-37-0P	860164-39-2P	860164-41-6P
860164-43-8P	860164-45-0P	860164-47-2P
860164-49-4P	860164-51-8P	860164-53-0P
860164-55-2P	860164-57-4P	860164-59-6P
860164-61-0P	860164-63-2P	860164-65-4P
860164-67-6P	860164-69-8P	860164-71-2P
860164-73-4P	860164-75-6P	860164-77-8P
860164-79-0P	860164-81-2P	860164-83-6P
860164-85-8P	860164-87-0P	860164-89-2P
860164-91-6P	860164-93-8P	860164-95-0P
860164-97-2P	860164-99-4P	860165-01-1P
860165-03-3P	860165-05-7P	860165-07-7P
860165-09-9P	860165-11-3P	860165-13-5P
860165-15-7P	860165-16-8P	860165-18-0P
860165-20-4P	860165-22-6P	860165-24-8P
860165-26-0P	860165-28-2P	860165-30-6P
860165-32-8P	860165-34-0P	860165-36-2P
860165-38-4P	860165-40-8P	860165-42-0P
860165-44-2P	860165-46-4P	860165-48-6P
860165-50-0P	860165-52-2P	860165-54-4P
860165-56-6P	860165-58-8P	860165-60-2P
860165-62-4P	860165-64-6P	860165-66-8P
860165-68-0P	860165-70-4P	860165-72-6P
860165-74-8P	860165-76-0P	860165-78-2P
860165-80-6P	860165-82-4P	860165-84-0P
860165-86-2P	860165-88-6P	860165-90-8P
860165-92-0P	860165-94-2P	860165-96-4P
860166-00-0P	860166-02-2P	860166-04-8P
860166-04-7P	860166-06-9P	860166-08-1P
860166-10-5P	860166-12-7P	860166-14-9P
860166-16-1P	860166-18-3P	860166-20-7P
860166-22-9P	860166-24-1P	860166-26-3P
860166-28-5P	860166-30-9P	860166-32-1P
860166-34-3P	860166-36-5P	860166-38-7P
860166-40-1P	860166-42-3P	860166-44-5P
860166-46-7P	860166-48-9P	860166-50-3P
860166-52-5P	860166-54-7P	860166-56-9P
860166-58-1P	860166-60-5P	860166-62-7P
860166-64-9P	860166-66-1P	860166-68-3P
860166-70-7P	860166-72-9P	860166-74-1P
860166-76-3P	860166-78-5P	860166-80-9P
860166-82-1P	860166-84-3P	860166-86-5P
860166-88-7P	860166-90-1P	860166-92-3P
860166-94-5P	860166-96-7P	860166-98-9P
860167-00-6P	860167-02-8P	860167-04-0P
860167-06-2P	860167-08-4P	860167-10-8P
860167-12-0P	860167-14-2P	

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; prepn. of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 860167-16-4P 860167-18-6P 860167-20-0P  
860167-22-2P 860167-24-4P 860167-26-6P  
860167-28-8P 860167-30-2P 860167-32-4P  
860167-34-6P 860167-36-8P 860167-38-0P  
860167-40-4P 860167-42-6P 860167-44-8P  
860167-46-0P 860167-48-2P 860167-49-3P,  
9-(Methylsulfonyl)-2,3,4,8,9,10,11,12-octahydro-1H-  
[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine  
860167-52-8P, 9-(Methylsulfonyl)-3-(pyridin-3-yl)-9,10,11,12-  
tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(drug candidate; preparation of fused imidazo ring compds. as inducers of  
cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 860170-00-9P, 6-Amino-9-(methylsulfonyl)-9,10,11,12-tetrahydro-  
8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-3-ol  
860173-13-3P, 9,10,11,12-Tetrahydro-8H-  
[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine hydrochloride  
860173-16-6P, tert-Butyl 6-amino-11-[(tert-butylidimethylsilyl)oxy]-  
11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline-9(10H)-

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)

860160-34-5P	11-[(tert-butylidimethylsilyl)oxy]-9-	
	(methylsulfonyl)-9,10,11,12-tetrahydro-8H-	
	[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine	
860160-40-3P	860160-41-4P	
	9-(Methylsulfonyl)-9,10,11,12-tetrahydro-8H-	
	[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine	
860167-51-7P	3-Bromo-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-	
	[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine	
860167-54-0P	860167-56-2P	860167-58-4P
860167-60-8P	860167-62-0P	860167-64-2P
860167-66-4P	860167-68-6P	860167-70-0P
860167-72-2P	860167-74-4P	860167-76-6P
860167-78-8P	860167-80-2P	860167-82-4P
860167-84-6P	860167-86-8P	860168-88-0P
860168-92-2P	860168-94-4P	860168-96-6P
860168-93-0P	860168-95-2P	860168-97-4P
860168-99-6P	860169-01-3P	860169-03-5P
860169-05-7P	860169-07-9P	860169-09-1P
860169-11-5P	860169-13-7P	860169-15-9P
860169-17-1P	860169-19-3P	860169-21-7P
860169-23-9P	860169-25-1P	860169-27-3P
860169-29-5P	860169-31-9P	860169-33-0P
	860169-35-0P	860169-36-6P
	860169-40-0P	860169-42-2P
	860169-46-6P	860169-48-4P
	860169-52-4P	860169-54-6P
	860169-59-1P	860169-61-5P
	860169-67-1P	860169-69-3P
	860169-73-9P	860169-75-7P
	860169-82-0P	860169-85-3P
	860169-90-0P	860169-93-2P
	860169-98-8P	860170-01-0P
	860170-07-6P	860170-10-1P

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 860160-35-6P, 6-Amino-9-(methylsulfonyl)-9,10,11,12-tetrahydro-  
8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-1-ol  
860160-42-5P 860162-53-4P 860162-55-6P  
860162-57-8P 860162-59-0P 860162-61-4P  
860162-63-6P 860162-65-8P 860162-67-0P  
860162-69-2P 860162-71-6P 860162-73-8P  
860162-75-0P 860162-77-2P 860162-79-4P  
860162-81-0P 860162-83-2P 860162-85-4P  
860162-87-4P 860162-89-6P 860162-91-0P  
860162-93-2P 860162-95-4P 860162-97-6P  
860162-99-8P 860163-01-0P 860163-03-2P  
860163-05-9P 860163-07-1P 860163-09-3P  
860163-11-7P 860163-13-9P 860163-15-1P  
860163-17-3P 860163-19-5P 860163-21-7P  
860163-23-9P 860163-25-1P 860163-27-3P  
860163-29-7P 860163-31-1P 860163-33-3P  
860163-35-5P 860163-37-7P 860163-39-9P  
860163-41-3P 860163-43-5P 860163-45-7P  
860163-47-9P 860163-49-1P 860163-51-5P  
860163-53-7P 860163-55-9P 860163-57-1P  
860163-59-3P 860163-61-5P 860163-63-7P  
860163-65-1P 860163-67-3P 860163-69-5P  
860163-71-9P 860163-73-1P 860163-75-3P  
860163-77-5P 860163-79-7P 860163-81-1P  
860163-83-3P 860163-85-5P 860163-87-7P  
860163-89-9P 860163-91-3P 860163-93-5P  
860163-95-7P 860163-97-9P 860163-99-1P  
860164-01-9P 860164-03-1P 860164-05-3P  
860164-07-4P 860164-09-6P 860164-11-0P  
860164-13-2P 860164-15-4P 860164-17-6P  
860164-19-8P 860164-21-2P 860164-23-4P  
860164-25-6P 860164-27-8P 860164-29-0P


L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)

carboxylate 860173-17-7P,  
11-[(tert-butylidimethylsilyl)oxy]-9,10,11,12-tetrahydro-8H-  
[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine hydrochloride  
860173-23-5P, 3-Bromo-9,10,11,12-tetrahydro-8H-  
[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine  
860173-35-9P, tert-butyl 6-amino-3-benzoyloxy-11,12-dihydro-8H-  
[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline-9(10H)-carboxylate  
860173-36-0P, 3-Benzoyloxy-9,10,11,12-tetrahydro-8H-  
[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine dihydrochloride  
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(intermediate; prepn. of fused imidazo ring compds. as inducers of  
cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 1043593-39-0P  
RI: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of fused imidazo ring compds. as inducers of cytokine  
biosynthesis for treatment of viral and neoplastic disease)

IT 1044675-88-8  
RI: PRPH (Prophetic)  
(Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and  
[1,5]diazocane fused imidazo ring compounds as inducers of cytokine  
biosynthesis for treatment of viral and neoplastic diseases)

RN 1044675-88-8 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitrn fhitstr l13 tot

L13 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on SYN (Continued)  
 AN 2006:67628 ZCAPLUS  
 DN 145:145757


II Preparation of chiral fused [1,2]imidazo[4,5-c] ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases  
 Griesgraber, George W.; Kshirsagar, Tushar A.; Celebi, Abdulaziz A.; Johannessen, Sarah C.; Danielson, Michael E.; Rice, Michael J.; Wurst, Joshua R.

PA 3M Innovative Properties Company, USA  
 SO PCT Int. Appl., 257 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006074003	A2	20060713	2005WO-US0047258	20051229
WO--2006074003	A3	20071122		
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CS, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, NG, NA, SD, SL, SE, TE, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, BA, BP, OA			
AU--2005322898	A1	20060713	2005AU-000322898	20051229
CA-----2592904	A1	20060713	2005CA-002592904	20051229
EP-----1831236	A2	20070912	2005EP-000855766	20051229
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, BR, HK, IU			
JP--2008526754	T	20080724	2007JP-000549590	20051229
US--20080269192	A1	20081030	2007US-000813039	20070628
PRAI 2004US-00640614P	P	20041230		
2005US-00697257P	P	20050707		
2005WO-US0047258	W	20051229		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS CASREACT 145:145757; HARPAT 145:145757  
 GI



AB Title compds. I [X = a bond, straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; X' = straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; provided that the sum of the

L13 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on SYN (Continued)  
 ring C atoms contributed by X and X' = 1-3; Z = O, NH and derivs., N-SO2-NH- and derivs., etc.; X1 = a bond, alk(en/yn)ylene; R1 = (un)substituted alk(en/yn)yl, hetero/aryl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, etc.; or when taken together RA and RB form a (un)substituted fused hetero/aryl ring, or a (un)substituted fused 5 to 7 membered satd. ring; and their pharmaceutically acceptable salts], were prepd. as immunomodulators for inducing cytokine biosynthesis in animals (no data) and in the treatment of diseases including viral and neoplastic diseases (no data). For example, II was prepd. via cyclocondensation of diamine III (prepn. given) with Et 2-chloroethanimidoate-HCl, followed by TBCMS-deprotection in the presence of tetrabutylammonium fluoride/cyclization in THF, oxidn., and amination with NH4OH. Certain I modulated cytokine biosynthesis by inhibiting prodn. of interferon  $\alpha$  and/or tumor necrosis factor TNF- $\alpha$  when tested in an in vitro blood cell system (no data).

II 898818-25-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of chiral fused [1,2]imidazo[4,5-c] ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

II 898818-25-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of chiral fused [1,2]imidazo[4,5-c] ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)


RN 898818-25-2 ZCAPLUS

CN Formic acid, compd. with 9,10,11,12-tetrahydro-12-methyl-9-(methylsulfonyl)-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine (1:7) (CA INDEX NAME)

CM 1

CRN 898818-24-1

CMF C16 H19 N5 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

=> d his

(FILE 'HOME' ENTERED AT 12:53:49 ON 08 JAN 2010)

FILE 'ZCAPLUS' ENTERED AT 12:54:31 ON 08 JAN 2010  
L1 1 US20070167476/PN

FILE 'REGISTRY' ENTERED AT 12:54:56 ON 08 JAN 2010

FILE 'ZCAPLUS' ENTERED AT 12:54:56 ON 08 JAN 2010  
L2 TRA L1 1- RN : 1057 TERMS

FILE 'REGISTRY' ENTERED AT 12:55:16 ON 08 JAN 2010  
L3 1057 SEA L2  
L4 529 L3 AND NRRS>=4  
L5 STR  
L6 37 L5  
L7 STR L5  
L8 36 L7  
L9 665 L7 FULL  
SAV TEM J895C2A/A L9  
L10 342 L9 AND L3  
L11 323 L9 NOT L10

FILE 'ZCAPLUS' ENTERED AT 13:01:51 ON 08 JAN 2010  
L12 1 L10  
L13 1 L11

=>